A statistically significant increase was noted for NET nucleosomes, thrombin–antithrombin complex (TAT), thrombomodulin (TM), and CRP in breast cancer patients with reduced LVEF > 10% (p < 0.05) compared to the patients with normal LVEF in response to DOX-based chemotherapy. This evidence concerns the gene TAT and breast carcinoma.